MAPT and Alzheimer disease: In 2018, the National Institute on Aging and Alzheimer's Association Research Framework shifted the definition of AD in living people from a syndromal to a biological construct.5 The new research framework defines AD by using a variety of biomarkers, which are grouped into those of Aβ deposition, pathologic tau protein, and neurodegeneration (A/T/N).5